(VDVDODELOHFH÷LQL]\HQLOLN™

Procapil™

Türkçe
 PROCAPIL™
ÖZET

$oÕNODPD d|]HOWLLoHULVLQGHWDPDPOD\ÕFÕDNWLIPDGGHNRPELQDV\RQX

,1&, DGÕ: Butylene Glycol (ve) Water (Aqua) (ve) PPG-26-Buteth-26 (ve)
PEG-40 Hydrogenated Castor Oil (ve) Apigenin (ve)
Oleanolic Acid (ve) Biotinoyl Tripeptide-1

Objektif olarak gösterilen dermokozmetik aktivite:

ƒ In vitro oDOÕúPDODU
• Peptitbiyotinil-GHK
QÕQVDoIROLNO]HULQGHNLYDUOÕ÷ÕoDOÕúPDVÕ-
%,2$/7(51$7,9(6oDOÕúPDVÕ
• .OWUOHQPLúVDoIROLNOOHUL]HULQGH\DúODQPD\ÕJHFLNWLUPHoDOÕúPDVÕ
(BIO-(&oDOÕúPDVÕ
2 ppm biyotinil-GHK (yani, %1 PROCAPIL™ YDUOÕ÷ÕQGD  SSP
 —0 0LQR[LGLOŠ YDUOÕ÷ÕQGD RODQD EHQ]HU úHNLOGH kontrolde
ROGX÷XQGDQGDKDVWQELUE\PHHOGHHGLOPLúWLUSSP
biyotinil-GHK (yani, %2.5 PROCAPIL™) ile büyüme kontrolde
ROGX÷XQGDQGDKDID]ODROPXúWXU
• PROCAPIL™ ile gen aktivasyonu (DNA dizisi)
%,2$/7(51$7,9(6oDOÕúPDVÕ

ƒ In vivo oDOÕúPDODU
D\OÕNSODVHERNRQWUROONOLQLNGHQH\'(506&$1/DERUDWXYDUODUÕ
Telojen DúDPDVÕQÕQELUG|QJVQNDSVD\DQD\OÕNNOLQLNGHQH\LQ
VRQXoODUÕPROCAPIL™ ile tedavi edilen grupta oral Finastéride®
WHGDYLVLQH NÕ\DVOD DQDMHQWHORMHQ RUDQÕQGD EHOLUJLQ ELU DUWÕú
J|VWHUPLúWLU

gQHULOHQNXOODQÕPGR]X %3

*YHQOLN81,7,6&KDUWHUED÷ODPÕQGDRQD\ODQPÕúWÕU
Talep üzerine sunulacak raporlar: HET CAM testi
uzman raporu
øQVDQODU]HULQGHSDWFKWHVWL
RIPT
Ames testi

PROCAPIL™
 ødø1'(.ø/(5

1. *ø5øù 1 - 7/41

2. 6$d'g.h/0(6ø1ø*(&ø.7ø50(<(<g1(/ø.6('(50$.216(37ø 8 - 9/41

3. (7.ø1/ø.7(67/(5ø 10 - 35/41
In vitro oDOÕúPDODU
.OWUOHQPLúVDoIROLNOOHULHNVSODQWODUՁ]HULQGHoDOÕúPD
(Saç folikülü üzerinde peptit Biyotinil-GHK¶QÕQYDUOÕ÷Õ -
%,2$/7(51$7,9(6oDOÕúPDVÕ
.OWUOHQPLúVDoIROLNOOHUL]HULQGH\DúODQPD\ÕJHFLNWLUPHoDOÕúPDVÕ
(BIO-(&oDOÕúPDVÕ
PROCAPIL™ ile gen aktivasyonu (DNA dizisi)
In vivo oDOÕúPD
D\OÕNSODVHERNRQWUROONOLQLNGHQH\'(506&$1/DERUDWXYDUODUÕ

4. SONUÇ 36 - 37/41

5. REFERANSLAR 38 - 40/41

EK 41/41

12/2009/V3

PROCAPIL™
 1/41
1. *ø5øù

6DoÕQ VRQXQGD VDo oL]JLVL EHOLUJLQ ELU úHNLOGH JHULOH\HQH NDGDU JQEHJQ
LQFHOPHVL EX HUNHN QIXVXQXQ |QHPOL ELU RUDQÕQÕQ KHU JQ \DúDGÕ÷Õ
GHQH\LPGLU (QGLúH YH KD\DO NÕUÕNOÕ÷Õ VRQUDVÕQGD WHVOLP ROPD ELUH\LQ NDID
DUNDVÕE|OJHKDULoWPNDIDWDVÕQÕHWNLOH\HQNHOOLNOHELUOLNWHN|Wüleyici bir öz-imaj
belirlemesine neden olur.

$ORSHVL  \DúÕQGDQ LWLEDUHQ HUNHNOHULQ 

VLQL HWNLOHU YH RQ \ÕOGD ELU 
DUWDU%XGD\DúÕQGDNLHUNHNOHULQ\DUÕVÕQGDQID]ODVÕQÕQNHOOLNWHQPX]GDULS
ROGX÷XDQODPÕQDJHOLU
Kozmetik segmentindeki erkek WDOHELQLQJFNROD\OÕNODDQODúÕODFDNWÕU
%DúODQJÕoWD RUWD VHYL\HGH RODQ DORSHVL JHQo HULúNLQOHUGH PH\GDQD JHOHELOLU
YHYDNDODUÕQ
LQGHDQGURMHQLNHWL\RORML\HVDKLSWLU

0LODWWDQ  \ÕO |QFH +LSRNUDW KDUHP D÷DODUÕQÕQ DVOD NHOOHúPHGL÷LQL

J|]OHPOHPLú GROD\ÕVÕ\OD NHOOL÷LQ |]HO RODUDN HULO IDNW|UH ED÷OÕ ROGX÷XQX
NHúIHWPLúWLU

%X DQGURMHQH ED÷OÕ ROJX NDGÕQODUGD NHOOL÷LQ QHGHQ GDKD D] ROXúWX÷XQX GD
DoÕNODPDNWDGÕU %X GH]DYDQWDM \DOQÕ]FD KDVWDOÕN VWUHV \D GD ED]HQ
|VWURMHQOHULQ EHOLUJLQ ELU úHNLOGH GúS GRODúÕPGDNL testosteronun
GHQJHOHQHPHGL÷L menopoz VRQUDVÕ G|QHP JLEL EHOLUOL NRúXOODU DOWÕQGD RUWD\D
oÕNPDNWDGÕU

%XHUNHNYHNDGÕQHúLWVL]OL÷LNDGÕQODUÕNRUXPDNWDGÕUYHNDGÕQODUÕQ
GHQD]Õ
DúÕUÕVDoG|NOPHVL\DGD\HUOHúLNNHOOLNWHQúLND\HWetmektedir.
.DGÕQODUÕQ VDoÕQÕQ OHKLQH ELU EDúND IDUNOÕOÕN GD YDUGÕU  \ÕOD NDGDU RODQ VDo
|PU EHOLUJLQ ELU úHNLOGH GDKD X]XQGXU HUNHNOHUGHNL VDo |PU LVH RUWDODPD
RODUDN EX VUHQLQ \DUÕVÕ NDGDUGÕU %X GXUXP NDGÕQ VDoÕQÕQ XODúDELOHFH÷L
PDNVLPXPX]XQOX÷X GDDoÕNODPDNWDGÕU

PROCAPIL™
 2/41
)DNDW VDo E\PH G|QJV KHU LNL FLQVL\HWWH GH D\QÕGÕU YH  DUGÕúÕN
DúDPDGDQ ROXúXU

Her iki saç da, keratinositlerin hücre bölünmesiyle saç N|NYHDUGÕQGDQVDo

DODQÕROXúWXUDQELUGHUPDOSDSLOODVHYL\HVLQGHROXúXU
6Do IROLNOQQ WDEDQÕQGD \HU DODQ KHU ELU SDSLOOD
GDKLOL ELU VDDWH
 X\DUDN
GR÷DOVDo\HQLOHQPHVLQLWHWLNOHPHNLoLQJHUHNHQELUE\PHPHVDMÕDOÕU

- øON DúDPD \D GD E\PH DúDPDVÕ anajen RODUDN ELOLQLU YH  LOD  \ÕO
sürer.
- øNLQFLDúDPDLVHLODKDIWDVUHQ E\PHGXUPDVÕQGDQROXúXU%X
katajen DúDPDVÕGÕU
- hoQF DúDPD LVH VDoÕQ GÕúDUÕ\D oÕNWÕ÷Õ telojen DúDPDVÕGÕU. Yüzeye
oÕNÕú|QFHVLQGHN|NDODQÕQÕQJHULOH\LSVDoNÕOÕ\XYDVÕQÕQKLSRGHUPLVWH
\DNODúÕN  PP GHULQOLNWH \HU DOÕU D\UÕOPDVÕ JHUHNWL÷L LoLQ EX DúDPD
ROGXNoD\DYDúJHUoHNOHúLU%XVUH\DNODúÕNLODD\GÕU

%XG|QJ|PUER\XQFD\DNODúÕNNH]WHNUDUODQÕU

ƒ S$d025)2-(1(=ø

Saç \D GD YFXW NÕOODUÕ GHUPLV YH HSLGHUPLV DUDVÕQGDNL HWNLOHúLPOH RUWD\D
oÕNDU
Epidermal mesajla harekete geçirilen fibroblastlar, primer bir filiz (2)
ROXúWXUPDNLoLQGHUPLVLLoHGR÷UXNDWOD\DQELUHSLGHUPDOSODNDROXúXPXQX
tetikleyen keratinositlere ELUVLQ\DOKD]ÕUODUYHLOHWLU

%|\OHFHSULPHUILOL]JHOHFHNWHNLGHUPDOSDSLOOD\ÕROXúWXUPDNLoLQoHYUHGHNL
ILEUREODVWODUÕVWDELOL]HHGHQPHVDMODUJ|QGHULU
6RQRODUDNILOL]GHUPDOSDSLOODWDUDIÕQGDQJ|QGHULOHQPHVDMODUÕQHWNLVLDOWÕQGD
kademeli olDUDNYHVDoIROLNOQHIDUNOÕODúÕU

PROCAPIL™
 3/41
3$86DUGÕQGDQVDoPRUIRMHQH]LQLQIDUNOÕHYUHOHUL

.HUDWLQRVLWOHUGHQJHOHQELUVLQ\DOLQDUGÕQGDQ
HSLGHUPDOSODNDQÕQKD]ÕUODQPDVÕ
1. Evre

3ULPHUILOL]ROXúXPXLOHSODNRGXQGHUPLV
LoLQGHLoHGR÷UXNDWODQPDVÕ

2. Evre

)LEUREODVWODUGDQJHOHQELUVLQ\DOLQDUGÕQGDQ
GHUPDOSDSLOODQÕQ\HQLEDúOD\DQROXúXPX

3. Evre

4. Evre )DUNOÕODúPD'HUPDOSDSLOODGDQJHOHQELU
VLQ\DOHFHYDEHQVDoIROLNOROXúXPX

5. Evre

dRNVD\ÕGDKDEHUFLEXGHUPDO-HSLGHUPDOGL\DORJGDHWNLOHúLPHJLUHUYH
EXQODUÕQNHVLQUROOHULKHQ]DoÕ÷DNDYXúWXUXODPDPÕúWÕU

PROCAPIL™
 4/41

ƒ S$d9(+h&5(',ù,0$75ø6

Saç büyümesinin temel ELOHúHQOHULQGHQ ELUL GH NHUDWLQRVLW YH ILEUREODVWODUÕQ

\R÷XQODúWÕ÷ÕGHUPDOSDSLOODLoHULVLQGHNLGHUPLVYHHSLGHUPLVDUDVÕQGDNLIL]LNVHO
HWNLOHúLPGLU
'HUPDOSDSLOODLNLKFUHSRSODV\RQXDUDVÕQGD\DNÕQWHPDVÕNRUX\DQYHVDo
NÕOÕ\XYDVÕQÕQE\PHVLLoLQJHUHNHQNLP\DVDOLOHWLúLPLGHVWHNOH\HQNRODMHQOHU
YH JOLNR]DPLQRJOLNDQODU DoVÕQGDQ |]HOOLNOH ]HQJLQ ELU E|OJHGLU %X PDWULV
ELOHúHQOHULQLQVDoE\PHVLLoLQELUPDWULVPRWRUXRODUDNGúQOHELOHFHNRODQ
GHUPRHSLGHUPDOELUOHúLPYHGHUPDOSDSLOODQÕQE\NNÕVPÕQÕQILEURQHNWLQLOH
WDEDQ PHPEUDQÕQÕ GD ROXúWXUPDVÕ GROD\ÕVÕ\OD NRODMHQ ,9 YH ODPLQLQH LOLúNLQ
|QHPLQYXUJXODQPDVÕJHUHNLU-$+2'$ve ark., 1992), (ALMOND-ROESLER
B. ve ark., 1997).

$UD\] PDWULVL PROHNOOHULQLQ FLOW YH X]DQWÕODUÕQÕQ E\PHVL YH

IDUNOÕODúPDVÕQGDR\QDGÕ÷ÕPHUNH]LUROLQVDQFLOGLQLQHPEUL\RMHQH]LKDNNÕQGDNL
7$0,2/$.,6oDOÕúPDVÕLOHDoÕNELUúHNLOGHUHVPHGLOPLúWLU
YHKDIWDDUDVÕQGDNLLPQRIORUHVDQHWLNHWOHPHVDoNÕOÕ\XYDVÕQÕQN|N
NÕQÕQGDJoOODPLQLQNRODMHQ,9YHILEURQHNWLQ\R÷XQODúPDVÕJ|VWHUPHNWHGLU

%X ELOHúHQOHU EDúODQJÕoWD \DOQÕ]FD VDo N|NQQ HSLWHO JHUPLQDO KFUHOHULQGH

PHYFXWWXU  KDIWD EXQODU NDGHPHOL RODUDN N|N NÕQÕQÕ HOH JHoLULU YH
DUGÕQGDQ VDoÕQ RUWD\D oÕNWÕ÷Õ DODQD YH GHUPRHSLGHUPDO ELUOHúLPe göç eder
(21. haftada DEJ).

 KDIWDGDQ |QFHNL EDúODQJÕo HYUHVLQGH GHUPRHSLGHUPDO ED]DO ODPLQD

VHYL\HVLQGHYLPHQWLQPHYFXWWXUYHLONKHPLGHVPR]RPROXúXU-9. hafta).

0DWULV ELOHúHQOHULQLQ NOWUOHQPLú LQVDQ VDoÕ IROLNOOHULQLQ KD\DWWD NDOPDVÕ YH

büyümesindeki önemi WARREN R. ve ark.WDUDIÕQGDQGDJ|VWHULOPLúWLU

PROCAPIL™
 5/41

Arayüz matris proteinlerinin rolü, özellikle yeni saç rekonstrüksüyonuna yol

açDQ ROD\ODU GL]LOLPLQGH DoÕN ELU úHNLOGH UHVPHGLOPLúWLU .|N \DSD\ RODUDN
NÕVÕPODQGÕUÕOÕSDOÕQGÕ÷ÕQGDGÕúN|NNÕQÕQÕQNHUDWLQRVLWOHULULVNOLDODQÕQDúD÷ÕVÕQD
göç eder. )LEUREODVWODU NHUDWLQRVLWOHULQ NDUúÕVÕQD \HUOHúLU Bu yeni arayüz
DODQÕQGDNRODMHQ,9ODPLQLQYHILEURQHNWLQLoHUHQELUPDWULVROXúXU<HQLELU
GHUPDOSDSLOOD\DSÕODQGÕUÕOÕUYHIDDOL\HWHJHoHU&2/,1ve ark., 1992).

.RODMHQ,9YHODPLQLQ
LQJHQHOOLNOHNHUDWLQRVLWOHUWDUDIÕQGDQVHQWH]OHQGL÷LYH
laminin 5'in dermoepidermal kohezyon ve \DUD L\LOHúPHVL VÕUDVÕQGD
NHUDWLQRVLWOHULQ J|oQGH NULWLN YH \HUL DOÕQDPD] ELU URO R\QDGÕ÷Õ J|] |QQGH
EXOXQGXUXOPDOÕGÕU52866(//(3

ƒ S$d9((.6ø./ø./(5

%L\RWLQ\DGD+YLWDPLQLEHVOHQPH\ROX\ODYFXGDDOÕQDQWHPHOELUYLWDPLQGLU

%L\RWLQHNVLNOL÷LFLOWYHX]DQWÕODUÕQGDDQRPDOLOHUH\RODoDULQFHµWDUDQDPD\DQ¶
saç (SHELLEY ve ark.DORSHVLSXOODQPDNDúÕQWÕYHGHUPDWLW)5,**
ve ark., 1989; FRITSCHE ve ark., 1991).
%L\RWLQ HNVLNOL÷LQH HQ KDVVDV KFUHOHU Q|URQODU YH NHUDWLQRVLWOHUL LoHULU
(SUORMALA ve ark., 2002). Erkekteki fizyolojik eksiklikler mental gerilik ve
cilt anomalilerine yol açar. Cilt ve beyinin ortak embriyolojik kökeni dikkate
DOÕQGÕ÷ÕQGDEXWDPDPHQEHNOHQPHGLNELUGXUXPGH÷LOGLU

(SLGHUPLVWH EL\RWLQ |]HOOLNOH IDUNOÕODúPDQÕQ JHo G|QHP VLWRNHUDWLQOHULQLQ

ROXúXPXQXG]HQOHU)5,76&+(ve ark., 1991).

PROCAPIL™
 6/41

%L\RNLP\DVDO ELU EDNÕú DoÕVÕQGDQ EL\RWLQ NHQGLVL LoLQ SURVWHWLN JUXEX

ROXúWXUGX÷XPLWHNRQGUL\DONDUERNVLOD]ODUÕQGR÷UXLúOHYJ|UPHVLLoLQNDoÕQÕOPD]
bir enzimatik kofaktördür.

Mitekondriyal enzimlerin (piruvat, propiyonil-CoA, 3-metil krotinil-CoA ve

asetil-&R$NDUERNVLOD]ODUÕOLVLQNDOÕQWÕODUÕQDNRYDOHQWED÷OÕEL\RWLQDNWLIIRUPD
d|QGUOPú KDOL\OH LVH NDUERNVLEL\RWLQ SLUXYDW .UHEV G|QJV YH
oksaloasetat (lipojenez) gibi akseptörlere CO2 JUXSODUÕQÕQDNWDUÕOPDVÕQÕVD÷ODU
bu nedenle biyotin mitekondriyal metabolizmada kritik bir kofaktördür.

ƒ S$d'g.h/0(6ø1ø<$9$ù/$70$.ødø1.8//$1,/$1675$7(-ø.+('()/(5

Birinci hedef
%LULQFL KHGHIEHOLUJLQELUúHNLOGHDQGURMHQLNWLU: amaç dihidrotestesteron (DHT)
üretimini 5α-UHGNWD] \DYDúODWPDNWÕU g]HOOLNOH GHUPDO SDSLOODGD \HU DODQ
DQGURMHQ UHVHSW|UOHULQH E\N \DNÕQOÕ÷Õ ROPDVÕ QHGHniyle bu metabolit (kan
WDUDIÕQGDQVD÷ODQDQWHVWRVWHURQGDQGDKDDNWLIWLU$1'(566216
'+7VDoIROLNOQN|UHOWHUHNYH\DNÕQ]DPDQGDJHOLúWLULOHQELUKLSRWH]HJ|UH
(SAWAYA ve ark., 2001), kaspaz 3 YDVÕWDVÕ\OD pro-apoptotik bir mekanizma
ile hareket eder.

Ciltte 5α-UHGNWD]ÕQL]RIRUPXPHYFXWWXUIDNDWα1 formunun yüz seviyesinde

EN] DNQH YH GHUPDO SDSLOOD VHYL\HVLQGH VDo IROLNOQGH GDKD DNWLI ROGX÷X
görülürken, αIRUPXQXQLoYHGÕúN|NNÕQÕVHYL\HVLQGHGDKDoRNYDUROGX÷X
UDSRUHGLOPLúWLU%$<1(ve ark., 1999).

PROCAPIL™
 7/41
/¶2UpDO HNLEL *(567  ELU \DSÕDNWLYLWH LOLúNLVL oDOÕúPDVÕQGD α2-
UHGNWD]ÕQVSHVLILNLQKLELW|UOHULQLQVSHVLILNα1-UHGNWD]ODUÕya da karma α1- ve
α2-UHGNWD]ODUÕQÕQDNVLQHNOWUOHQPLúVDoIROLNOOHUL]HULQGHDNWLIROPDGÕ÷ÕQÕ
J|VWHUPLúWLU

Finasterid (5α2-UHGNWD]Õ ]HULQGHNL H\OHPLQGHQ GROD\Õ DVOÕQGD SURVWDWLN

KLSHUWURIL LoLQ JHOLúWLULOHQ ELU LODo JLEL NDUPD α1- ve 5α2-redüktaz
LQKLELW|UQQ NXOODQÕPÕ EHOLUJLQ ELU úHNLOGH JHULOH\HQ ELU VDo oL]JLVL J|UOHQ
KDVWDODUGDNLVDoG|NOPHVLQGHEHOLUJLQELUD]DOPDVD÷ODPÕúWÕU
Böylelikle 5α-UHGNWD]ÕQÕQ EDVLW LQKLELV\RQX DUDFÕOÕ÷Õ\OD  \ÕO VRQUD DQDMHQ
DúDPDGDVDoDUWÕúÕHOGHHGLOPLúWLU9$11(67(ve ark., 2000).

%X HWNLQLQ '+7 VHYL\HOHULQGHNL ORNDO GúúH  ED÷OÕ ROGX÷X

GúQOPúWU %X VD\HGH '+7 QRUPDO VDo GHULVLQGHNL NRQVDQWUDV\RQGD
PHYFXWKDOHJHOPLúWLU'$//2%ve ark., 1994).

øNLQFLKHGHI
øNLQFL KHGHI NDQGÕU: iyi NDSLOHU SHUI]\RQ DVOÕQGD ELU DQWLKLSHUWDQVLI RODUDN
NXOODQÕODQ ELU SHULIHUDO YD]RGLODW|U RODQ 0LQR[LGLOŠ
LQ EHNOHQPHGLN EDúDUÕVÕQÕ
DoÕNODPDN LoLQ JHOLúWLULOHQ PHNDQL]PDGÕU øOJL oHNLFL \DQ HWNLVL RODQ \HQL VDo
E\PHVL LODFÕQ KLSHUWDQVL\RQX WHGDYL HWPHN LoLQ NOLQLN NXOODQÕPÕ\OD
NHúIHGLOPLúWLU

$UWÕUÕOPÕú NDSLOHU SHUI]\RQD ED÷OÕ HWNLQLQ D]ÕPVDQPDPDVÕ JHUHNPHVLQH

UD÷PHQ 0LQR[LGLOŠ
LQ IROLNOGH KDOL KD]ÕUGD IDUNOÕODúPÕú RODQ NHUDWLQRVLWOHULQ
DNWLISUROLIHUDV\RQXQXVD÷OD\DUDNKDUHNHWHWWL÷LGHELOLQPHNWHdir (BOYERA N.,
1997).

Üçüncü hedef
Minoxidil®'in hiper-proliferatif etkisine (100 µM'den az konsantrasyon) ek
olarak, yüksek dozda (milimol düzeniyle) bir pro-IDUNOÕODúPD HWNLVL GH UDSRU
HGLOPLúWLU %X HWNL IROLNOOHUGHNL ORNDO DNPODV\RQ LOH X]XQ Vreli tedavide
HOGH HGLOHELOLU 6RQXo RODUDN VDo G|NOPHVL JHFLNWLULOLU 'ROD\ÕVÕ\OD hiper-
proliferatif etki ve pro-IDUNOÕODúPDHWNLVL KHGHILROXúWXUXU

PROCAPIL™
 8/41
2. 6$d'g.h/0(6ø1ø*(&ø.7ø50(<(<g1(/ø.6('(50$.216(37ø

Günümüzdeki saç morfojenezi DQOD\ÕúÕ YH DORSHVL\L WHWLNOH\HQ \D GD

úLGGHWOHQGLUHQ SRWDQVL\HO VHEHSOHULQLQ SURJUHVLI NHúIL ÕúÕ÷ÕQGD ROGXNoD
NDUPDúÕN YH oRN IDNW|UO ELU PHNDQL]PDQÕQ EXOXQGX÷X DoÕNWÕU )ROLNO MHQH]L
YH VDo E\PH G|QJVQQ LOHUOHPHVLQL NRQWURO HWPH\H oDOÕúPDN EDKVH
girmek gibi ELUúH\GLU.

'DKDVÕ oRN \DNÕQ ]DPDQGD \DSÕODQ MHQHULN oDOÕúPDODU PXWDV\RQODUÕ DORSHVL

LOHLOLúNLOL|QHPOLELUJHQPLNWDUÕHQD]J|VWHUPLúWLU6('*:,&.-RKQ*4
Magazine, 1999).

%X QHGHQOH úX DQD NDGDU \DSÕOPÕú LOHUOHPHOHUL özellikle anti-androjenik ve

YD]RGLODW|U ELOHúHQOHU NRQXVXQGD RODQODUÕ LKPDO HWPHPHQLQ |QHPOL ROGX÷X
RUWD\DoÕNPDNWDGÕU
'ROD\ÕVÕ\OD 6('(50$ EH KHGHIOHU ]HULQGH H\OHP J|VWHUHQ ELWNL N|NHQOL LNL
DNWLIPDGGH VHoPLúWLU α1- ve 5α2-UHGNWD]ODUÕQÕQ LQKLELV\RQX LoLQ oleanolik
DVLW/RYH\O\+HPVOH\DN|NOHULQGHQ|]WOHQPLúYHYD]RGLODV\RQLoLQDSLMHQLQ
QDUHQFL\HGHQ|]WOHQPLúIODYRQRLG

$UGÕQGDQ 6('(50$ VDo DQNRUDMÕ NRQVHSWL KHGHIOL H\OHPH VDKLS EX LNL
\DNODúÕPÕJoOHQGLUPLúWLU
6DoÕQFLOWLoLQGHGDKDL\L³N|NOHQPHVL´VD÷ODQDELOL\RUVDDUD\]VHYL\HVLQGHNL
NLP\DVDO KDEHUFLOHULQ DOÕúYHULúOHULQGHNL L\LOHúPH LOH ELUOLNWH WXWXQPD DUWÕúÕ
(dermal papilla - VDo IROLNO HOGH HGLOHFHNWLU %X DUD\]OHPH DUWÕúÕ DQDMHQ
DúDPDVÕQÕQNDOLWHVLYHVUHVL]HULQGHSR]LWLIELUHWNL\HVDKLSRODFDNWÕU%HQ]HU
úHNLOGH VDo NÕQÕ YH GHUPLV DQNRUDMÕQGDNL DUWÕú WHORMHQ DúDPDQÕQ
EDúODQJÕFÕQÕQJHFLNWLUHFHNWLU

Bu amaçla, pro-matris aktiviteleri verilen bir peptit dizilimi seçtik: Matrikinler

serisinin bir üyesi olan Glisil-Histidil-Lisin peptiti (MAQUART ve ark., 1999) ve
EXQX+YLWDPLQLQHEL\RWLQED÷ODGÕN%XYLWDPLQLQHNVLNOL÷LLQFHDORSHVLNVDo
FLOWVDUNPDVÕYHGHUPDWLWH\RODoDU
Bu Ɣekilde, çift matris ve metabolik eylem beklentisiyle yeni bir teƔekkül
oluƔturulmuƔtur: vitamin taƔŦyan bir peptit olan Biyotinil-GHK.

PROCAPIL™
 9/41
%XQHGHQOHĮ-UHGNWD]ÕQÕLQKLEHHWPHNLoLQROHDQROLNDVLWNDQSHUI]\RQXQX
DUWÕUPDN LoLQ DSLMHQLQ YH JoOHQGLULOPLú E\PH LOH VDo DQNRUDMÕQGD DUWÕú LoLQ
biyotinil-GHK olmak üzere üç aktif madde yeni konseptte bir araya
JHWLULOPLúWLU

PROCAPIL™

352&$3,/ŒELOHúHQKHGHIOHUL

Biyotinil-GHK →
øoN|NNÕQÕ

Biyotinil-GHK →
'ÕúN|NNÕQÕ

Biyotinil-GHK →
Dermal papilla

Oleanolik asit→5-α-
redüktaz antagonizmi

Apijenin →
vazodilasyon

%HOLUOLJHQOHULQ'1$GL]LVLDNWLYDV\RQXLOHRQD\ODQDQH\OHPPHNDQL]PDVÕ

matris güçlendirici HWNLOHU NOWUOHUGH LQVDQ VDoÕ IROLNO HNVSODQWODUÕQÕQ
E\PHVLYHD\OÕNSODVHERNRQWUROONOLQLNGHQH\LQVRQXoODUÕEXGRV\DQÕQ
NRQXVXQXROXúWXUPDNWDGÕU

PROCAPIL™
 10/41

3. (7.ø1/ø.7(67/(5ø

In vitro oDOÕúPDODU

.OWUOHQPLúVDoIROLNOOHULHNVSODQWODUՁ]HULQGHoDOÕúPD
(Saç folikülü üzerinde peptit Biyotinil-GHK¶QÕQYDUOÕ÷Õ-
%,2$/7(51$7,9(6oDOÕúPDVÕ

Prensibi
dDOÕúPD ƒ&¶GH ELU QHPOHQGLUPH E|OPHVL LoLQGH 3%6 RUWDPGD NOWUOHQPLú
RODQLQVDQFLOGLHNVSODQWODUÕDEGRPLQDOSODVWLNRQXVXQGD\UWOPúWU
(NVSODQWODUÕQSHSWLWWe bekletilmesini müteakip, piliyal bölge çevresinin seçilen
ORNDOL]DV\RQXQX LQFHOHPHN ]HUH NÕVÕPODUÕQ LPQRKLVWRNLP\DVDO oDOÕúPDVÕ
\UWOPúWU

Protokol
6Do IROLNOO FLOW HNVSODQWODUÕ  VDDW  SSP SHptit mevcudiyetinde inkübe
edilir ve peptitsiz eksipiyana PDUX] EÕUDNÕOPÕú RODQ NRQWURO HNVSODQWODUÕ LOH
NDUúÕODúWÕUÕOÕU
Tespitler ELUELULQLQD\QÕVÕSDUoDüzerinde yürütülür.
 VDDW VRQUD KHU ELU ND\QD÷ÕQ PHUNH]LQGHQ -PP EL\RSVL oÕNDUWÕOÕU YH VÕYÕ
nitrojen içinde hemen dondurulur.
 —P NDOÕQOÕ÷ÕQGDNL NÕVÕPODU GRQDQ ELU PLNURWRP NULRVWDW NXOODQÕODUDN
\DSÕOPÕú ROXS VRQUD NXUXWXOPXú YH VDELWOHQPLúOHUGLU Biyotinil-GHK,
VWUHSWDYLGLQSHURNVDWÕNDYUDPÕúRODQLPQRHWLNHWOHPHLOHWHVSLWHGLOPLúWLU

PROCAPIL™
 11/41
Sonuçlar
.ÕVÕPODUSHSWLWBiyotinil-*+.¶QÕQ DoÕNSHUL-SLOL\DOORNDOL]DV\RQXQXJ|VWHUPLúWLU
ANRQWUROHNVSODQWÕQÕQUHVPLVDo
NÕOÕ\XYDVÕHWUDIÕQGDHWLNHWOHPH\RN
(büyütme 20X)

BELWLúLNVDoNÕOÕ\XYDVÕHWUDIÕQGD
belirgin biyotinil-GHK lokalizasyonu
(büyütme 20X)

C;E\WPHLOHVDoÕQSHULIHUDO
HúPHUNH]OLDODQÕbiyotinil-GHK
WDUDIÕQGDQJoOELUúHNLOGH

DER\ODPVDONÕVÕPVDoX]XQOX÷X
ER\XQFDL\LELUGD÷ÕOÕPLOHVSHVLILN
biyotinil-GHK lokalizasyonu ve çevre
dokuda etiketleme yok (büyütme 20X)

dÕNDUÕP
Biyotinil-GHKKHGHILRODQVDoIROLNOOHULoHYUHVLQGH|]HOYDUOÕNJ|VWHUHQ
GD\DQÕNOÕSHSWLWWLU
PROCAPIL™
 12/41
.OWUOHQPLúVDoIROLNOOHUL]HULQGH\DúODQPD\ÕJHFLNWLUPHoDOÕúPDVÕ
(BIO-(&oDOÕúPDVÕ

Prensibi
0LNURJUDIW WUDQVSODQWDV\RQX GHYUHVL ED÷ODPÕQGD KD]ÕUODQPÕú RODQ çok
miktarda saç folikülleri PHILPOTT ve ark.WDUDIÕQGDQUDSRUODQPÕúRODQD
EHQ]HUELURUWDPDNOWUOHPHNLoLQWRSODQPÕúWÕU

Protokol
6DoIROLNOOHUL KDYD DUWÕ  &22 DWPRVIHU DOWÕQGD ƒ&¶GH  JQ D\UÕ D\UÕ
LQNEHHGLOPLúWLU
(NVSODQWODU PXKWHOLI JUXSODUD E|OQPúOHUGLU \DOQÕ]FD NOWU RUWDPÕQGDNL
kontrol grubu, pozitif kontrol gurubu (pozitif referans ürünü) ve peptit biyotinil-
GHK¶\DPDUX]EÕUDNÕODQWHVWJUXEX
KüOWURUWDPÕJQGHELUGH÷LúWLULOPLúWLU

Genel morfoloji gün EDúODQJÕoYHJQWDULKOHULQGHJ|]OHPOHQPLúWLU

(ú ]DPDQOÕ RODUDN IROLNOOHULQ ELU NÕVPÕ GDKD LOHUL LPQRKLVWRNLP\DVDO
oDOÕúPDODUÕ\UWPHN]HUHGRQGXUXOPXúWXU
Büyüme bir dijital NDPHUD NXOODQÕODUDN ' ' ' ' ' YH '
WDULKOHULQGHDOÕQDQJ|UQWOHUOHL]OHQPLúWLU

PROCAPIL™
 13/41
*HQHOPRUIRORMLVRQXoODUÕ

1- 6DoNÕOÕ\XYDVÕE\PHVL
%\PHWHVSLWOHULVDoNÕOÕ\XYDVÕQÕQVHUEHVWNÕVPÕQGD\DSÕOPÕúWÕUVDo
kökünün alt NÕVÕPODUÕKDULo

Kontrol folikülünün büyümesi, Biyotinil-GHK¶\DPDUX]EÕUDNÕODQ T0

T0 ile T14 günleri folikülün büyümesi, T0 ile T14

T7

T14

PROCAPIL™
 14/41
(OGHHGLOHQVRQXoODUDúD÷ÕGDNLJUDILNWHUDSRUODQPDNWDGÕU

'
GDQ'
HVDoNÕOÕ\XYDVÕE\PHVL

+%121

+%58 +%58

Kontrol Pozitif kontrol Biyotinil-GHK Biyotinil-GHK

Minoxidil® 2 ppm 2 ppm 5 ppm
(%1 PROCAPIL™) (%2.5 PROCAPIL™)

dÕNDUÕP

2 ppm peptit etkisi (yani %1 PROCAPIL™DOWÕQGDNRQWUROJXUXEXQGDQ

GDKD ID]OD E\PH HOGH HGLOPLú ROXS  SSP 0LQR[LGLOŠ¶LQ  —0
PHYFXGL\HWLQGHNLQH EHQ]HU ELU E\PH J|]OHQPLúWLU  SSP Biyotinil-GHK
(yani %2,5 PROCAPIL™LOHE\PHNRQWUROGHQGDKDID]ODROPXúWXU

PROCAPIL™
 15/41
2. .|NNÕQՁ]HULGH\DúODQPDJHFLNWLULFLIDDOL\HW

Prensibi
Hücre oR÷DOPD IDDOL\HWLQLNDQÕWODPDNLoLQPLWRWLNPDUN|U.øNXOODQÕOPÕúWÕU

Protokol
D0 ve D14 tarihlerinde GRQGXUXODQPLNURWRPNÕVÕPODUÕSHURNVLGD]ED÷OÕDQWL-
.LDQWLNRUXQDPDUX]EÕUDNÕOPÕúWÕU
.ÕVÕPODU ]HULQGH oR÷DODQ KFUHOHU NR\X NDKYHUHQJL ER\DQPÕúODUGÕU
0LNURVNRS DOWÕQGD VDo NÕOÕ \XYDVÕQÕQ N|N NÕQÕQÕQ GDKD DOW NÕVPÕQGD ELU VD\ÕP
\DSÕOPÕúWÕU.LPDrkörünün J|VWHUGL÷LEWQKFUHOHU VD\ÕOPÕúWÕUE|OJH

Ki67 mitoz kontrolü

D14

3.
Ki67 mitozu
Minoxidil® D14
2.

1.

Ki67 mitozu Biyotinil-

GHK D14
.LPLWR]VD\ÕP

PROCAPIL™
 16/41

Sonuçlar

Kültürün 14. gününde kontrol sac kökünde mitotik keratinositlerde azalma

J|UOPúWU. Bu durum hücre \DVODQPDVÕQÕ\DQVÕWÕU
Minoxidil® (BOYERA ve ark. WDUDIÕQGDQ\ÕOÕQGDUDSRUODQGÕ÷ÕJLEL—0
biyotinil-GHK¶QÕQ YH \DNODúÕN  —0 SSP biyotinil-GHK¶QÕQ \DSWÕ÷Õ JLEL
proliIHUDWLI IDDOL\HWLQL PXKDID]D HWPLúWLU Biyotinil-GHK ile elde edilen etki 10
—0 SSP 0LQR[LGLO Š NRQVDQWUDV\RQXQXQ  LOH  NDW DOWÕQGDNL
NRQVDQWUDV\RQODUGDHOGHHGLOPLúROPDVÕQDUD÷PHQoRNVWQGU

3. .|NNÕQÕYHGHUPDOSDSLOODbölgesinde bulunan ED÷OD\ÕFÕ

proteinlerin stimülasyonu

Prensibi
DermoepiGHUPDO NDYúD÷ÕQ NDOLWHVL NHUDWLQRVLWOHULQ LON ED]DO NDWPDQ GD\DQD÷Õ
]HULQGHNL YH \DSÕúDFDN ROGXNODUÕ ODPLQLQ  YH NRODMHQ ,9 DoÕVÕQGDQ ]HQJLQ
oRN\R÷XQED]DOODPLQDQÕQIRUPDV\RQXQDED÷OÕGÕU

PROCAPIL™
 17/41

Epidermis

Laminin 5

Bazal lamina

Kolajen IV
Dermis

'HUPRHSLGHUPDOELUOHúLP

PROCAPIL™
 18/41
a) .OWUOHPHGHQ  JQ VRQUD PRUIRORMLN J|]OHP NRQWUROQ GÕú NÕQ
WDUDIÕQGDG]OHúHQYHED]DOODPLQDVÕQÕND\EHGHQELUGHUPRHSLGHUPDOELUOHúLP
J|VWHUPLúWLU
Aksine, saç folikülü biyotinil-GHK LOH  JQ LQNEH HGLOGL÷L ]DPDQ ED]DO
ODPLQD NDOPÕú YH VLQ]RLGDO NDUDNWHULQL J|VWHUHUHN DoÕNoD oL]LOPLúWLU %X LNL
EXOJXJoOH\DSÕúDQYH\DúD\DQGHUPRHSLGHUPDOELUOHúLPL\DQVÕWÕU

Saç
DŦƔ kŦn
Dermo-
epidermal
ELUOHúLP

Dermoepidermal Dermis
birleƔim

Kontrol: 14 gün Tedavi Edilen: 14 gün

b) /DPLQLQ  YH NRODMHQ ,9 ED]DO PHPEUDQÕQ HSLGHUP YH GHUPLVLQ

HNOHQPHE|OJHVLQLQROXúXPXQGDYHVDoODUÕQROPDVÕGXUXPXQGDLVHN|NNÕQÕLOH
GHUPLV DUDVÕQGDNL E\N |QHPH VDKLS LNL SURWHRJOLNDQGÕU 0DWULV ELOHúHQOHUL
LPQRHWLNHWOHPHLOHKLVWRORMLNNÕVÕPODU]HULQGHQWHVSLWHGLOHELOLUOHU

PROCAPIL™
 19/41
.OWUOVDoIROLNOOHULQLNXOODQDUDN'WDULKLQGH\DSÕOPÕúRODQNRQWURONÕVÕPODUÕ
LOH J|VWHULOPLú ROGX÷X ]HU ODPLQLQ  YH NRODMHQ ,9 D\UÕFD GHUPDO SDSLOODGD
JoOúHNLOGHPHYFXWWXUODU-DKRGDve ark.,1992).

øoN|NNÕQÕQGDODPLQLQ
dermal papilla ile arayüz

øoN|NNÕQÕQGDYHGHUPDO
papillada kolajen IV

Protokol
'YH'|UQHNOHULQGHQGRQGXUXODQPLNURWRPNÕVÕPODUODPLQLQH7HEXYH
NRODMHQH ,9 &OLQLVFLHQFH |]J IORUHVDQ DQWLNRUODUD PDUX] EÕUDNÕOPÕúODUGÕU
(OGH HGLOHQ ER\DPD IORUHVDQ \HúLO ROPXúWX  1NOHLQLQ NDUúÕ ER\DPDVÕ
SURSLGL\XP L\RW NXOODQÕODUDN JHUoHNOHúWLULOPLú YH NÕUPÕ]Õ ER\DPD VRQXFX
YHUPLúWLU
*|]OHPOHU NÕO N|NQQ DOWÕQGDNL YH VWQGHNL IROLNOQ Lo E|OJHVL ]HULQGH
\UWOPúWUYHE|OJHEN]úHPDVD\IDVÕ

PROCAPIL™
 18/41
Sonuçlar

a) Laminin 5

Kontrol folikülünde,
ODPLQLQúHULGLGÕúN|N
NÕQÕWDUDIÕIROLNOQ
periferi), 14 gün sonra
ND\ERODQNDOÕQOÕN

a: D0 b: D14

%XEL]L'¶WHPXKWHOLIUQOHULQPHYFXGL\HWLQGHODPLQLQND\EÕQÕLQFHOHPH\H
J|WUPúWU

c: D14’te dermal papilla d: D14’te kök kŦnŦ

SSP—00LQR[LGLOŠPDUX]L\HWLDUGÕQGDQIROLNOJQVRQUDNDOÕQYH

LSEHQ]HULúHNLOGHNDODQELUODPLQLQúHULGLJ|VWHUPLúWLU

e: D14’te dermal papilla f: D14’te kök kŦnŦ

2 ppm (0.3 µM) Biyotinil-GHK PDUX]L\HWLDUGÕQGDQODPLQLQJQVRQUD

SDSLOODVHYL\HVLQGHYHGÕúN|NNÕQÕQGDJoOELUúHNLOGHPHYFXWRODUDN
NDOPÕúWÕU

PROCAPIL™
 21/41
b)Kolajen IV

Kontrolde kolajen T0'da çok

NDOÕQRODQ,9úHULGL7
JQQGH\DSÕVÕER]XQPXú
YH\R÷XQOX÷XQX
ND\EHWPLúWLU3DSLOOD
HWLNHWOHPHVLQLND\EHWPLúWLU
IRWR÷UDIODUJ|VWHULOPHPLúWLU

a: D0 b: D14

%XEL]L'¶WHPXKWHOLIUQOHULQPHYFXGL\HWLQGHNRODMHQ,9ND\EÕQÕ
LQFHOHPH\HJ|WUPúWU

c: D14’te dermal papilla G'¶WHN|NNÕQÕ

2 ppm (10 µM) Minoxidil®'e maruziyet, 14 gün sonra dermal papillada ve

N|NNÕQÕQGDNRODMHQ,9\R÷XQOX÷XQGDND\EÕWHWLNOHPLúWLU

e: D14’te dermal papilla f'¶WHN|NNÕQÕ

Biyotinil-GHK YDUOÕ÷ÕQGD  JQ VRQUD NRODMHQ ,9 GHUPDO SDSLOODGD JoO
ELUúHNLOGHPHYFXWRODUDNNDOPÕúHYHN|NNÕQÕVHYL\HVLQGHROGXNoDNDOÕQ
YH\DSÕODQGÕUÕOPÕúKDOGHROPXúWXUI*|]OHPOHQHQ\DSÕNRQWURO'
da (a)
RODQLOHQHUHGH\VHD\QÕGÕU

PROCAPIL™
 20/41
dÕNDUÕP

.|N NÕQÕQÕQ YH GHUPDO SDSLOODQÕQ  NRODMHQ ,9¶Q YH ODPLQLQ 

LQ
ELOHúHQOHUL]HULQGHSHSWLWbiyotinil-GHK¶QÕQNRUX\XFXYHRQDUÕFÕHWNLOHUL
DoÕNoD J|VWHULOPLúWLU  JQ ER\XQFD NOWUOHQPLú RODQ VDo IROLNO
HNVSODQWODUÕ ]HULQGH %Lyotinil-GHK¶QÕQ etkisi Minoxidil®
NRQVDQWUDV\RQXQGDQNDWGDKDGúNROPDVÕQDUD÷PHQ0LQR[LGLOŠ
H
J|UHGDKDEHOLUJLQROPXúWXU

*HQHO PRUIRORML DoÕVÕQGDQ biyotinil-GHK FDQOÕ ELU N|N NÕQÕQÕQ PLWR]

Ki67) muhafaza edilmesiyle ve dermis üzerine ankorajdan sorumlu olan
SURWHLQOHULQ NRODMHQ ,9 YH ODPLQLQ  \DSÕúPDVÕQGDQ VRUXPOX
\DSÕODQPDODUÕ DUWWÕUPDN RODQ VDo IROLNO NHUDWLQRVLWOHUL  JQON
NOWU ]HULQGH oRN EHOLUJLQ ELU \DúODnma geciktirme faaliyeti
VD÷ODPÕúWÕU

PROCAPIL™
 22/41

352&$3,/ŒLOHJHQDNWLYDV\RQODUÕ
%,2$/7(51$7,9(6oDOÕúPDVÕ

Prensibi
'1$ GL]LVL oDOÕúPDVÕ KFUH IRQNVL\RQODUÕ LOH LOJLOL \DUDUODUÕ LoLQ VHoLOHQ 
JHQGHQ ROXúDQ ELU SDQHOL NXOODQÕU dDOÕúPD \XNDUÕ-UHJOH  YH DúD÷Õ-regüle
PDUN|U JHQOHUL J|VWHUPLú ROGX÷XQGDQ NHUDWLQRVLW YH ILEUREODVW SRSODV\RQ
]HULQGHNR]PHWLNHWNHQPDGGHVLQLQHWNLVLQLQWDQÕPODQPDVÕQÕRODQDNOÕNÕODU

Protokol
'1$ GL]LVL oDOÕúPDVÕ 6NLQ(WKLFŠ \HQLGHQ ROXúWXUXOPXú LQVDQ HSLderm
örneklerinin PROCAPIL™’in (3 etken madde içeren kompleks: biyotinil-GHK,
ROHDQROLNDVLWYHDSLMHQLQPHYFXGL\HWLQGHLQNEHHGLOPHVL\OH\DSÕOPÕúWÕU
øQNEDV\RQ  VDDW VUPúWU +FUHOHUGH PHYFXW P51$ '1$ VD÷ODPDN
LoLQWHUV\|QOND\GHGLOPLúYHNRQWUol kültürlerine NDUúÕ RNXQDNOÕELUVLQ\DOHOGH
HWPHNLoLQE\WOPúWU57-PCR).
Sonuçtaki görüntü PROCAPIL™ WDUDIÕQGDQ \XNDUÕ UHJOH HGLOPLú RODQ YH\D
DúD÷Õ UHJOH HGLOPLú RODQ JHQOHULQ  VDDW VRQUDNL görüntülerinden bir
enstantanedir.

Sonuçlar
Takip eden sayfalardaki tablolar kontrole NDUúÕ EHOLUJLQ ROGX÷X GLNNDWH DODQ
VRQXoODUÕJ|VWHULUHQD]SR]LWLIYH\DQHJDWLIGH÷LúLNOLN
øOJLOL oHúLWOL KFUHOHUGH GDKD NoN GH÷LúLNOLNOHU  LOH  DUDVÕQGD
J|]OHQGL÷L]DPDQEXGH÷LúLNOLNOHUELU|OoGHPHNDQLN|QHPLRODQGH÷LúLNOLNOHU
RODUDNGLNNDWHDOÕQPÕúWÕU

PROCAPIL™
 23/41

Kontrole NDUúÕ \XNDUÕUHJOHJHQOHUYH

SURWHLQNRGODPDODUÕ

PROCAPIL™’e maruz kalma

%
DOWÕQGD3URFDSLOŒ¶\HPDUX]NDOPD
Kompleks proteinlerin yapŦƔmasŦ
Desmozomal proteinler 1&3 (Dezmogleinler) %135 / %138
Dezmokollin 1 %146
Fibronektin reseptörüβ-alt ünitesi %134
Vimentin %138
Laminin baŒlama proteini %146
øQWHJULQβ1 &β2 %134 / %144
Antioksidan enzimler
Tiyoredoksin peroksidazlarŦ (TDPX2 & AO372) %152 ve 174
SOD (mitokondriyal & sitosolik) %150 ve 169
Metalotiyoneinler MTH & HMT %188 ve 190
CYP b-UHGNWD]Õ %160
Stres proteinleri
HSP 27 %164
HSP 90 %139
Anti-enflamatuar proteinler
ĀQWHUIHURQγ antagonisti %135
Hücre metabolizmasŦ enzimleri
Mitokondriyal trifonksiyonel protein & Asil CoA prekürsörü %123 ve 128
Ornitin dekarboksilaz %132
Glutamin sentetaz %136
Asil CoA transferaz %137
ø]RVLWUDWGHKLGURMHQD] %189
iNOS %143
NADP izositrat dehidrojenaz %189
3UROLIHUDV\RQIDUNOÕODúPDPDUN|UOHUL
Proliferasyon hücresi nükleer antijeni (PCNA) %191
Sitokeratinler 10, 14 ve 16 %154 / 150 / 144
Steroid reseptör koaktivatörü %160

PROCAPIL™
 24/41

Kontrole NDUúÕ DúD÷ÕUHJOHJHQOHU

(100%)YHSURWHLQNRGODPDODUÕ

PROCAPIL™’e maruz kalma

%
DOWÕQGD3URFDSLOŒ¶\HPDUX]NDOPD
Pro-enflamatuar proteinler
øQWHUIHURQγ reseptörü -%57
Anjiyojenik ve matris-yeniden modelleme faktörleri
Vitronektin -%52
TIMP1/TIMP2 -%43 / -%24
Antikimotripsin α1 -%43
Lisil hidroksilazlar 1&2 -%50 / -%29
Heperan sülfat proteoglikan -%40
Kolajen 1 alt ünitesi -%46
Hücre proliferasyonu regülasyonu
5HWLQRLNED÷ODPDSURWHLQOHUL&5$%3&5$%3 -%34 / -%63
Vit. D3. reseptörü -%40

Yorum

<XNDUÕ\DGR÷UX UHJOHHGLOHQKFUHPHWDEROL]PDVÕHQ]LPOHUL\OHHQ]LPHED÷OÕ

RODUDNLOHDUDVÕQGD\NVHNE\PHIDDOL\HWLQH\|QHOPLúRODQELU
KFUH SURILOLQL \DQVÕWÕU +FUHOHULQ \NVHN VHYL\HGH PHWDEROLN DNWLYLWH
WDUDIÕQGDQ VLVWHPDWLN RODUDN UHWLOHQ VHUEHVW RNVLMHQ UDGLNDOOHULQH NDUúÕ
NRUXPDNJHUHNWL÷LLoLQDQWLRNVLGDQNRUX\XFXHQ]LPOHUGHLOLúNLOHQGLULOPLúWLU

Hücre proliferasyonu nükleer antijeni (PCNA), streoid reseptör ortak-

DNWLYDW|UOHULYHYHVD\ÕOÕSrROLIHUDV\RQYHD\UÕOPDVitokeratinleri gibi
hücre proliferasyonunun markörleri pro-D\UÕP IDDOL\HWLQL J|VWHUHUHN -21$.
 EHOLUJLQ úHNLOGH DQFDN D\UÕFD SURWHLQ +63 ¶OH LOJLOL RODUDN
\XNDUÕUHJOHROPXúODUGÕU
)DUNOÕODúPD\D ED]Õ \DSÕúWÕUPD SURWHLQOHULQGH ELU DUWÕú HúOLN HWPLúWLU KFUHQLQ
ED]DO ODPLQD\D ODPLQLQ ED÷ODPD SURWHLQL YLPHQWLQ LQWHJULQ α ve β)
ED÷ODQPDVÕQÕ NDSVD\DQ KFUHOHU YH \DSÕúPD\Õ YH KFUH NDWPDQODUÕQGDNL
NHUDWLQRVLWOHULQGH]PRJOHLQOHUGH]PRNROLQOHU\D\ÕOPDVÕQÕRODQDNOÕNÕODQODUYH
son olarak çeviUHQ GHUPLVH GH]PRJOHLQOHU GH]PRNROLQOHU DQNRUDMÕ
VD÷OD\DQODUDUDVÕQGDED÷ODQWÕ\ÕRODQDNOÕNÕODQODU

PROCAPIL™
 25/41
Her ikisinin güçlü anti eQIODPDWXDU ELU NDWNÕ \DSWÕ÷Õ DúD÷Õ UHJODV\RQOX DUWDQ
interferon antagonisti (+%135) ile birlikte gen interferon reseptörünün azalan
ifadesiyle (-\DQVÕWÕOPÕúWÕU

Bu nedenle, hücre proliferDV\RQX \RODNODUÕQÕQ EX \RODNODU ]HULQGHNL QHJDWLI

HWNLVL\OH IDNW|UOHUGH ELU D]DOPD\OD \R÷XQODúÕUNHQ PDWULV \HQLGHQ
modellemesinin ve anjiyojenezLQNDSVDPÕúROGX÷XJHQOHUJHoLFLRODUDNDúD÷Õ
UHJOHGLUOHU &5$%3  VLWRSOD]PLN UHWLQRWLN DVLW ED÷ODPD SURWHLQOHUL YH
vitamin D3 reseptörü (hücre proliferDV\RQX YH D\UÕPÕ LoLQ WUDQVNULSVL\RQ
faktörü).

Markörlerin güçleri:
Dezmogleinler NHUDWLQRVLW DUDVÕ \DSÕúPD LoLQ YD]JHoLOPH] RODQ YH VDoÕQ GÕú
N|NNÕQÕQÕQIRUPDV\RQXQDNDWNÕGDEXOXQDQ\DSÕúWÕUPDSURWHLQOHULGLU*$552'
ve ark., 2002; NUBER ve ark., 1996)
%XQODU D\UÕFD GHUPDO \DSÕODUÕQ N|N NÕQÕQÕ VDELWOHPH\L GH NDSVDUODU
dezmoglein genlHUL|OGUOPúRODQIDUHQLQWHORMHQVDoODUÕQÕprematüre olarak
kaybeder. (HANAKAWA Y., 2002).

Vimentin HSLWHO\DO GRNX YH VDoÕQ PRUIRMHQezlerinde bir rol oynayan

PHVHQNLPD GHUPLV NHUDWLQRVLWOHU LOH VHQWH]OHQPLú RODQ PDWULVWHQ ROXúXU
(TAMIOLAKIS ve ark., 2001).

6LWRNHUDWLQOHU  IDUNOÕODúPD  YH  VDoÕQ PRUIRMHQ YH NHUDWLQRVLW
proliferasyonu) ve metabolik enzimler ve hücre mitozu (proliferasyon hücresi
QNOHHU DQWLMHQ PDUN|UOHUL \HQL GRNXODUÕQ PRUIRMHQL GR÷UXOWXVXQGD
keratinositik hiperaktiviteyi karakterize ederler.
Retinoik asit için D3 vitamini reseptörünün ve reseptörlerinin (CRABP 1/2)
JHoLúL RODUDN DúD÷Õ UHJOH ROGX÷XQX QRW HWPHN LOJLQoWLU 7UDQVNULSVL\RQ
inhibisyonu de novo '1$ VHQWH] WHúYLNLQL KFUH proliferasyonunu (KROHN
ve ark., 2003) YHIROLNOHULGDPH\L%,//21,NDOGÕUÕU
5HVHSW|UIDDOL\HWLD\QÕ]DPDQGDGLKLGURWHVWRVWHURQXQ'+7DQGURMHQOHULJLEL
VWHURLGOHUH GH ED÷OÕ ROGXNODUÕQGDQ UHVHSW|UQ GúN VHYL\H LIDGHVL D\UÕFD
KRUPRQDODNWLYDV\RQXQ\RNOX÷XQX\DQVÕWÕU

PROCAPIL™
 26/41

5HWLQRLG VWHURLG YH ' YLWDPLQL UHVHSW|UOHUL DUDVÕQGD YH NR-efektörlerinin

PHYFXGL\HWLQGH YH\D \RNOX÷XQGD  KDILI HWNLOHúLPOHU YDUGÕU %X UHVHSW|UOHU
bundan ötürü saç folikülü morfojenezinde önemi faktörlerdir.
Bu nedenle PROCAPIL™’in etkisi saçmorfojeni ve büyümesi için esas olan
faktörleri kapsar.
<XNDUÕ UHJOH PXKWHOLI JHQOHU DUDVÕQGD SHSWLW biyotinil-GHK JHQH \DSÕúWÕUPD
ve proliferasyonu), biyotin (güçlü mitokondriyal faaliyet) ve oleanolik asit
(CRABP 1 ve 2’nn ve D3 vitamini \ROODUÕQÕQGHDNWLYDV\RQXSDWHQWWLU

In vitroYHULOHU]HULQGHQoÕNDUÕP

6HQWHWLN HSLGHUP ]HULQGH '1$ GL]LVL oDOÕúPDVÕ YH NOWUOHQPLú LQVDQ

VDoÕ HNVSODQWODUÕ KDNNÕQGDNL PRUIRORMLN oDOÕúPD LOH UHWLOHQ YHULOHULQ
ND\GDGH÷HUWXWDUOÕOÕ÷ÕDúD÷ÕGDNLOHULQRWHWPH\HGH÷HUGLU

• .L LOH \NVHN \DúODQPD JHFLNWLUPH IDDOL\HWL DUWDQ JHQHO

PRUIRORML N|N NÕQÕ YH SDSLOOD DQWLRNVLGDQ VHOOHU HQ]LPOHU YH
proliferDV\RQXQ3&1$PDUN|UOHULIDDOL\HWHJHoPLúWLU
• <DSÕúWÕUPDNRPSOHNVLQLQ\NVHNde novo protein sentezi (kolajen
IV, laminin 5, vimentin, dezmogleinler ve dezmokolinler).
• +FUH PHWDEROL]PDVÕQÕQ PLWRNRQGUL\DO HQ]LPOHU YH E\PH
DNWLYDV\RQXQXQ VDo NÕOÕ \XYDVÕ YH VLWRNHUDWLQOHU   YH 
EHOLUJLQX\DUÕOPDVÕ

<XNDUÕGDNLYHULOHUVDoPRUIRMHQH]LQLWHúYLNHGHQYHN|NNÕQÕQÕQGHUPLVH
DQNRUDMÕQÕQJoOHQGLUHQELUUQQSURILOLLOHWXWDUOÕGÕU

hUQ GD\DQÕNOÕ ROXS |]HOOLNOH VDoD \HUOHúWLULOPLúWLU IROLNO ER\XQFD

imüno-lokalizasyon, çevre dokuda yok).

PROCAPIL™
 27/41
In vivo oDOÕúPDODU

D\OÕNSODVHERNRQWUROONOLQLNGHQH\'(506&$1/DERUDWXYDUODUÕ

Prensibi

Sac dökülmesi problemi erkeklerde daha fazla J|UOG÷QGHQ, söz konusu

VRUXQXQPHYFXWROGX÷XHUNHNGHQHNOHUOHELUoDOÕúPDEDúODWÕOPÕúWÕU%LUWHORMHQ
G|QHPLWDPDPHQNDSODPDNLoLQD\OÕNELUoDOÕúPDVUHVLVHoLOPLúWLU

$QDMHQ G|QHPGHNL VDo PLNWDUÕ YH WHORMHQ G|QHPGHNL VDF PLNWDUÕQÕQ $7
parametresi) zaman içiQGHVDSWDQPDVÕYHJ|]OHPOHQPHVLLoLQYLGHRWULNRJUDP
PHWRGXNXOODQÕOPÕúWÕU

Protokol

ƒ Dahil etme kriterleri

<DúODUÕ  LOH  DUDVÕQGD GH÷LúHQ .DINDV\D RULMLQOL YH VDoODUÕQÕQ ¶GHQ
ID]ODVÕQÕQ WHORMHQ GRQHPGH ROGX÷X WHVSLW HGLOHQ RWX] EHú HUNHN GHQHN GDKLO
HGLOPLúWLU

ƒ +DULoEÕUDNPDNULWHUOHUL

9HUWHNVWHJULVDo.DIDGHULVLKDVWDOÕNODUÕ
dDOÕúPDGDQ|QFHNLD\LoLQGHNRUWLNRVWHURLGOHULQLPQRVXSUHVDQODUÕQYH\D
retinoidlerin ya da bir hafta içinde anti-HQIODPDWXDUODUODUÕQDOÕQPDVÕ
6RQD\LoLQGH0LQR[LGLOŠ¶LQ\HUHOX\JXODPDVÕYH\DWRSLNDOYH\DRUDORODUDN
DOÕQDUDNYH\DWURSLNVDoWHGDYLVLúHNOLQGHKHUKDQJLELUORNDOµVDoND\EÕ
önleyici’ tedavisi.
.DIDGHULVLQLQWRSLNDOYH\DRUDOoDOÕúPDEDúODPDGan önce 4 hafta içinde
günlük friksiyon olarak anti-seboreik, kepek önleyici) tedavisi.
dDOÕúPDVÕUDVÕQGDEHVOHQPHYH\DHJ]HUVL]DOÕúNDQOÕNODUÕQÕQ
GH÷LúWLULOPHVL$ONROYHWWQQDúÕUÕNXOODQÕPÕ

PROCAPIL™
 28/41

ƒ Ürün uygulama

Ürün veya plasebo \XPXúDN PDVDM NXOODQÕODUDN EDú FLOGLQH JQGH  NH]
X\JXODQPÕúWÕU
PROCAPIL™ UHQNVL] OLNLW J|UQPO ROXS  RUDQÕQGD VXODQGÕUÕOPÕú DONRO
ORV\RQXRODUDNIRUPOHHGLOPLúWLU3ODVHERD\ÕUWHGLOHPH]QLWHOLNWHROPXúWXUHN
1'de verilen formül).

ƒ Uygunluk / Güvenlik

8\JXQOXNYHJYHQOLNNRQWUROOHULWHGDYLQLQYHKDIWDODUÕQGD
\DSÕOPÕúWÕU

7YH7D\ODUÕ]DPDQQRNWDODUÕQGDGHUPDWRORJWDUDIÕQGDQNDIDGHULVLQLQIL]LNL
ELUPXD\HQHVL\DSÕOPÕúYHGHQHNPODNDWÕLOHJYHQOLNGH÷HUOHQGLULOPLúWLU

ƒ Videotrikogram

.XOODQÕOPÕú RODQ VLVWHP ELU GLMLWDO J|UQW DOPD VLVWHPLQH ED÷ODQPÕú ILEHU
RSWLNOL PRELO ; REMHNWLILQ PRQWH HGLOPLú ROGX÷X 025,7(; 6&23(0$1Š
MS-500 marka bir videomikroskoptur.
*|UQWOHU'(506&$1/DERUDWXYDUODUÕQÕQJHOLúWLUPLúROGX÷X&2UNT-HAIR®
SURJUDPÕLOHDQDOL]HGLOPLúWLU
øúDUHWOHPHVRQUDVÕQGDD\QÕWÕUDúOÕVDoE|OJHVLQGHQRUWDODPDRODUDN\DNODúÕN
1cm2VDo7
GDYHD\VRQUDJ|UQWDOÕQPÕúWÕU

ø]OHQHQ SDUDPHWUHOHU VDoÕQ ER\X YH E\PH RUDQÕ YH DQDMHQ DúDPDGDNL
VDFODUÕQPLNWDUÕYHWHORMHQDúDPDGDNLVDoODUÕPLNWDUÕROPXúWXU

PROCAPIL™
 29/41

'PP
\HWÕUDúODPD

D48h: uzama ǻ 'sÕ DQDMHQ

8]DPD\RNOX÷X WHORMHQ

ƒ Saç Örnekleri: Morfolojik analiz ve kolajen IV ve laminin 5’in imüno

etiketlemesi.

7¶GD YH oDOÕúPDQÕQ VRQXQGD FÕPEÕ]ODU NXOODQÕODUDN DORSHVLN E|OJHQLQ

VÕQÕUÕQGDQ  DGHW VDo |UQHNOHQPLúWLU 7HGDYL JXUXEXQGDNL  GHQHN YH
SODVHERJXUXEXQGDNLNLúL|UQHNOHPH\HWDELWXWXOPXúWXU
Saçlar, analiz için BIO-EC’e gönderilmeden önce (12 adet saç %RXLQ VÕYÕVÕ
LoLQGHVDELWOHQPLúYH\DDGHWVDoKHPHQGRQGXUXOPXúWXU

PROCAPIL™
 30/41
Sonuçlar

a) Klinik deney

dDOÕúPD\DGDKLOHGLOHQGHQHNWHQ¶LPROCAPIL™ grubuna (37 ± \ÕOYH

17’si (38 ± \ÕOplasebo JUXEXQDWDKVLVHGLOPLúWLUPROCAPIL™ ve plasebo
JUXSODUÕQDWDKVLVHGLOHQGHQHNOHUUDVWJHOHVHoLOPLúOHUGLU

ƒ Güvenlik
PROCAPIL™  D\OÕN NXOODQÕP VUHVLQFH WP GHQHNOHU WDUDIÕQGDQ çok iyi
tolere HGLOPLúWLU.

ƒ Videotrikogram
.OLQLN oDOÕúPDODU PXKWHOLI GH÷HUOHQGLUPH NULWHUOHUL NXOODQDUDN VDo derisi
VD÷OÕ÷ÕQGD ELU WHGDYLQLQ HWNLOHULQL |OoPH\L DPDoODU 6Do \R÷XQOX÷X VDo
DGHGLFPð E\PH\HQLGHQ E\PH LGGLDVÕQGDNL UQOHU LoLQ NXOODQÕOÕU
$QDMHQYHWHORMHQDúDPDODUGDNLE\PHYH\DND\ÕSVDo\]GHOHUL\OHELUOLNWH
EX\]GHOHULQRUDQODUÕGDKDoRNVDoGHULVL]HULQGHNLVDoDQNRUDMÕQÕQYHVDo
FDQOÕOÕ÷ÕQÕQ KDOD PHYFXGL\HWLQH X\DUODQÕU %X VRQXQFX SDUDPHWUHOHU V|]
NRQXVXQHGHQOHoDOÕúPDLoLQVHoLOPLúOHUGLU

$QDMHQWHORMHQRUDQÕ

$úD÷ÕGDNL úHNLO EDúODQJÕoWD ve  D\ VRQUDNL DQDMHQWHORMHQ RUDQÕQÕQ  D\

VUHLOHRUDO\ROODNXOODQÕODQ)LQDVWHULGHŠLoLQ\D\ÕQODQDQYHULOHUOH9DQ1HVWH
YHDUNNÕ\DVODPDVÕQÕJ|VWHULU

PROCAPIL™ WHGDYLVLQLQD\VRQUDVÕQGDJ|QOOOHUDQDMHQDúDPDVDoODUÕQÕQ
RUDQÕQGD 7¶OD NDUúÕODúWÕUÕOGÕ÷ÕQGD ND\GD GH÷HU VWQONWH  S  
EHOLUJLQ ELU L\LOHúPH J|VWHUPLúOHUGLU 3ODVHER IDDO GH÷LOGLU 2UDO \ROOD DOÕQDQ
)LQDVWHULGHŠ LoLQ \D\ÕQODQDQ YHULOHUOe NÕ\DVODQGÕ÷ÕQGDPROCAPIL™’in kayda
GH÷HUELUDNWLYLWHVLQLQROGX÷XQXJ|VWHULU

PROCAPIL™
 31/41

Nitekim D\VRQUD)LQDVWHULGHŠLoLQ$7RUDQÕQGD7LOHNÕ\DVODQÕQFDÕOÕPOÕ

ELUIDUNOÕODúPDD\VRQUD¶HXODúDQIDUNOÕODúPDUDSRUODQPDNWDGÕU

40
T0 ile kŦyaslandŦŒŦnda A/T farklŦlaƔma

30

20

Finasteride®
11 ay
10

PROCAPILTM Finasteride®
4 ay 5 ay
0

352&$3,/Œ JUXEXQGD GHQHNOHULQ ¶VL $7 RUDQÕQGD ELU JHOLúPH

J|VWHUPLúOHUGLU YH  GHQHNWHQ ¶ LoLQ $7 DUWÕúÕ \HQL VDo PLNWDUÕQGD
DUWÕúVÕUDVÕ\ODYHROPXúWXU
Aksine, plasebo gurubunda anajen saçlarda bir azalma yönünde bir
H÷LOLPROPXúWXU
1.4
1.2
A/T oranŦnŦn farklŦlaƔmasŦ

1
(PROCAPILTM 4 ay sonra)

0.8
0.6
0.4
0.2
0
-0.2
-0.4
-0.6
18 Denek

%\PHRUDQÕ
dDOÕúPDQÕQ EDúODQJÕFÕ LOH ELWLPL NDUúÕODúWÕUÕOGÕ÷ÕQGD  HQH÷LQ RUWDODPD VDo
E\PH KÕ]ÕQGD EHOLUJLQ ELU GH÷LúLNOLN J|UOPHPLúWLU )DNDWPROCAPIL™ ile
WHGDYL HGLOHQ JUXSWD E\PH RUDQÕQGD ELU DUWÕú J|VWHUHQ  J|QOOGH
JHOLúPH\HGR÷UXELUH÷LOLP J|UOPúWU

PROCAPIL™
 32/41
3ODVHER JUXEXQGD RUWDODPD E\PH RUDQÕ Gúú H÷LOLPOL - ROPXú YH
GHQHNOHULQoR÷XQGDKHUKDQJLELUJHOLúPHJ|UOPHPLúWLUGHQHNWHQ
LQGH
%X VRQXoODU ELU VRQUDNL E|OPGH UHVLPOHUOH NDQÕWODQGÕ÷Õ ]HUH FLOWWHNL
VDo DQNRUDMÕ IDDOL\HWL VD\HVLQGH 352&$3,/Œ
LQ JHQHO ED÷ODPGD VDo
G|NOPHVL LOH LOJLOL JoO ELU PRGHUDW|U ROGX÷X oÕNDUÕPÕ \DSPDPÕ]D \RO
DoPÕúWÕU

b) 4 ay sonra saçtagözlemlenen PRUIRORMLNGH÷LúLPOHU

D\VRQUDJUXSODUDUDVÕQGDVDFÕQ\DSÕVÕQGDNLIDUNOÕOÕNODUWHORMHQVDoçekerek
NRSDUÕODQ|UQHNOHPHNXOODQÕODUDNVHULRODUDNJ|]OHPOHQPLúWLU

ƒ D\OÕN]DPDQQRNWDVÕQGDSODVHER\DNDUúÕPROCAPIL™¶LQIDUNOÕOÕNODUÕ

PROCAPIL™ ile tedavi edilen grupta saç köklerinin çok daha fazla
\DSÕODQGÕUÕOGÕ÷ÕJ|UOG

Plasebo T4 ay (kök) PROCAPIL™ T4 ay (kök)

Bunun ötesinde PROCAPIL™ LOHWHGDYLHGLOHQVDoL\LIDUNOÕODúPÕúKFUHED]OÕ

LoVDoNÕOÕ\XYDVÕLOJLOLRODUDNoRNQHWVDELWOHQPLúN|NNÕQODUÕLOHELUOLNWHD\UÕFD
oRNL\LELUNDOLWHGHGÕúDUD\]GHUPLViçinde ankoraj) gösterir.

3ODVHER7D\N|NNÕQÕ PROCAPIL™ T4 ay (kök kÕQÕ

PROCAPIL™
 33/41
ƒ Anajen ve telojen saçODULoLQ7LOH7D\DUDVÕQGDNLIDUN

'HQHNOHUGHQELULQGH7LOH7D\DUDVÕQGDJ|]HoDUSDQGH÷LúLNOLNOHUJ|]OHQPLúWLU
$úD÷ÕGDJ|VWHULOGL÷L]HUHWHORMHQVDoÕQkök E|OJHVLoRNEHOLUJLQúHNLOGH
L\LOHúPLúWLU

PROCAPIL™ T0 (kök) PROCAPIL™ T4 ay (kök)

$QDMHQVDoODUÕQN|NNÕQODUÕGDNDOÕQODúDUDNYHDoÕNoDWDQÕPODQDQKFUH
ED]ODUÕ\ODL\LOHúPLúWLU

PROCAPIL™ 7N|NNÕQÕ PROCAPIL™ 7D\N|NNÕQÕ

PROCAPIL™
 34/41

PROCAPIL™ JUXEXQGDN|NNÕQÕVDoÕQGÕúWDUDIÕQÕQ]HULQHRSWLPXPGHUPDO-
HSLGHUPDO \DSÕúPD\Õ VD÷OD\DUDN PNHPPHO \DSÕODQPÕú ED]DO ODPLQD LOH
\NVHNNDOLWHGHJ|]OHQPLúWLU
øo N|N NÕQÕ WDUDIÕ ]HULQGH LVH VDo NÕOÕ \XYDVÕ EXOXQDQ ankoraj bölgeleri
J|]OHQPLúWLU
$NVLQHSODVHERJXUXEXQGDEXLNLE|OJHoRN\DSÕODQPÕúGH÷LOGLU

Bazal
tabaka
'ÕúN|N
NÕQÕ

øoNÕQVDoNÕOÕ
\XYDVÕQGDNL
ankoraj bölgesi)

Plasebo T4 ay PROCAPIL™ T4 ay

Kolajen IV ve laminin 5 markörleri ile ilgili imünoflüoransan bulgular

|QFHNLEXOJXODUÕWDNYL\HHWPLúWLU

PROCAPIL™ grubundaki telojen köklerde daha büyük laminin 5 flüoresan

N|NNÕQÕJ|]OHQPLúWLU

Plasebo T4 ay PROCAPIL™ T4 ay

PROCAPIL™
 35/41

$\UÕFDWHORMHQkökün kolajen IV etiketlenmesi de PROCAPIL™ gurubunda

dahaEHOLUJLQROPXúWXU

Plasebo T4 ay PROCAPIL™ T4 ay

In vivo YHULOHU]HULQGHQoÕNDUÕP

7DP ELU WHORMHQ DúDPD\Õ NDSVD\DQ  D\OÕN NOLQLN GHQH\LQ VRQXoODUÕ

PROCAPIL™ ile tedavi edilen gurupta oral Finastéride® tedaisi
X\JXODQDQ WHGDYL\H J|UH DQDMHQWHORMHQ RUDQÕQGD E\N ELU DUWÕú
J|VWHUPLúWLU

%X EXOJX 352&$3,/Œ YH 3/$6(%2 JXUXSODUÕQGDNL ELUNDo GHQHNWHQ

DOÕQPÕúRODQVDo|UQHNOHULkonusundaki morfolojik bulgularla mükemmel
úHNLOGHD\QÕGR÷UXOWXGDGÕU

7HORMHQ VDo ]HULQGH GHUPLVH L\L DQNRUDM LoLQ \DSÕODQPÕú YH G]HQOL
ELU ED]DO ODPLQD LOH PNHPPHO ELU N|N NÕQÕQÕQ \HQLGHQ ROXúXPX
\DSÕODQPÕúWÕU %X \DSÕúWÕUPD NRPSOHNV SURWHLQOHULQLQ kolajen IV’ün
YHODPLQLQ¶LQGDKDE\NPHYFXGL\HWLLOHWH\LWHGLOPLúWLU
øo N|N NÕQÕ VDo NÕOÕ \XYDVÕ YH NÕQ DUDVÕQGDNL \DSÕúPD PRWLIOHULQL
J|VWHUPLúWLU

PROCAPIL™
 36/41
4. GENEL ÇIKARIM

PROCAPIL™, saç dökülmesinden sorumlu üç olguyu hedef alan bir

potent Saç Dökülmesini Önleme kompleksidir:

• 5
-UHGNWD]ÕWHVWRVWHURQX'+7
\HG|QúWUU
• Yetersiz kan perfüzyonu
• 'HUPDOSDSLOODGDVDoDQNRUDMÕEDúDUÕVÕ]OÕ÷Õ

352&$3,/ŒELUOLNWHKDUHNHWHGHQDNWLIPDGGHGHQROXúXU
• peptit Biyotinil-GHK, narenciyeden özütlenen bir flavonoid
olan ve vazodilatör etkisine sahip tutunma
• SURWHLQL DSLMHQLQ VD\HVLQGH VDo DQNRUDMÕ ]HULQGH H\OHP
gösterir
• ROHDQROLNDVLW/RYH\O\+HPVOH\DN|NOHULQGHQ|]WOHQPLúWLU
ve5α−UHGNWD]ÕLOHGLKLGURWHVtosteron üretimini inhibe eder.

øQVDQIROLNOOHUL]HULQGHYHDNWLIOHúWLULOHQJHQOHULQDQDOL]HGLOPHVL\OH
elde edilen in vitro YHULOHUúXQODUÕJ|VWHUPLúWLU

• hUQQNDOÕFÕOÕ÷ÕVDoNÕOÕ\XYDVÕYHVHoLcL\HUOHúLPLQGHvis-
à-vis niteliktedir.
• Vimentin, dezmogleinler, dezmokollinler, laminin 5 ve
NRODMHQ,9WXWXQPDSURWHLQOHULWDUDIÕQGDQL\L\DSÕODQGÕUÕOPÕú
\DúD\DQELUN|NNÕQÕLOHVDoPRUIRORMLVLQGHJHOLúPH
• .HUDWLQRVLWLN oR÷DOPD YH VDo PRUIRMHQH]L ]HULQGH SRWHQW
aktivite

PROCAPIL™
 37/41
Oldukça pozitif olan bu özelliklerin in vivo HWNLOLROGX÷XJ|UOPúWU

7HORMHQHYUH\LNDSVD\DQD\OÕNNOLQLNGHQH\352&$3,/ŒLOHSODVHER\X
NDUúÕODúWÕUPÕúYHNRPSOHNVLQEHOLUJLQVDoG|NOPHVL|QOH\LFi aktivitesini
GR÷UXODPÕúWÕU

• PROCAPIL™ grubundaki 18 gönüllüden %67'si ortalama

DQDMHQWHORMHQ RUDQGD S RUDO X\JXODPD LOH  D\OÕN
WHGDYLGHQ VRQUD )LQDVWHULGHŠ LoLQ UDSRU HGLOHQOH D\QÕ
DUDOÕNWD EHOLUJLQ ELU JHOLúLP J|VWHUPLúWLU D\OÕN
352&$3,/ŒNXOODQÕPÕQGDQVRQUDED]ÕGHQHNOHU KDWWD

GDQID]ODELUJHOLúLPJ|VWHUPLúWLU
• dDOÕúPDQÕQ EDúÕQGD YH VRQXQGD DOÕQDQ VDo |UQHNOHULQLQ
morfolojik ve imünohistolojik analizleri, telojen saç kökü,
N|NNÕQÕYHODPLQLQLOHNRODMHQ,9\R÷XQOXNODUÕQÕQSODVHER
grubunda gözlemlenenin aksine PROCAPIL™ grubunda
EHOLUJLQELUúHNLOGHJHOLúWL÷LQLJ|VWHUPLúWLU

<XNDUÕGD\HUDODn sonuçlar dizisi, PROCAPIL™'in N|NNÕQÕUHMHQHUDV\RQX

DUDFÕOÕ÷Õ\ODGHUPLVWHWHORMHQVDoDQNRUDMÕQÕQDUWÕúÕQÕGHVWHNOH\HUHNH\OHP
J|VWHUGL÷LQLQ RQD\ODQPDVÕQÕ VD÷ODPDNWDGÕU'ROD\ÕVÕ\OD 352&$3,/Œ
VDoG|NOPHVLQL\DYDúODWÕUYHVDoIROLNOOHULQLQVD÷OÕ÷ÕQÕJHOLúWLULU

Optimum etki için PROCAPIL™'in %3'lük konsantrasyonda

NXOODQÕOPDVÕQÕ|QHULUL]

PROCAPIL™
 38/41
REFERANSLAR

ALMOND-ROESLER B ve ark., 1997

Cultured dermal papilla cells of the rat vibrissa follicule. Proliferative activity,
adhesion and reorganization of the extra-cellular matrix in vitro.
Arch Dermatol Res., 289 (12), p698-704

ANDERSSON S., 2001

Steroidogenic enzymes in skin.
Eur J Dermatol., aug, 11 (4), p293-95

BAYNE EK. ve ark., 1999

Immunohistochemical localization of types 1 and 2 5-alpha reductases in
human scalp.
Br J Dermatol., sep, 141 (3), p481-91

BILLONI ve ark., 1997

Expression of retinoid nuclear receptor superfamily members in human hair
follicles and its implication in hair growth.
Act. Derm. Venerol., 77 (5), p350-5

BOYERA N. ve ark., 1997

Biphasic effects of Minoxidil on the prolifération and differentiation of normal
human keratinocytes).
Skin Pharmacol., 10, p206-20

COLIN A.B. ve ark., 1992

Cellular and extracellular involvement in the regeneration of the rat lower
vibrissa follicule.
Development, 114, p887-97 (1992).

DALLOB AL. ve ark., 1994

The effect of Finasteride, a 5 alpha reductase inhibitor, on scalp skin
testosterone and DHT concentrations in patients with male pattern baldness.
J Clin. Endocrinol. Metab. , sep, 79 (3), p 703-6

FRIGG M ve ark., 1989

Clinical study on the effect of biotin on skin conditions in dogs
Schweiz. Arch. Tierheilk, 131, p 621-25

FRITSCHE A. ve ark., 1991

Pharmakologische wirkungen von biotin auf epidermiszellen
Schweiz. Arch. Tierheilk, 133, p 277-83

GARROD ve ark., 2002

Desmosomal adhesion: structural basis, molecular mechanism and
regulation.
Mol Membr Biol , Apr, 19 (2), p 81-94

PROCAPIL™
 39/41
GERST C ve ark., 2002
Type-1 steroid 5α−reductase is functionnally active in hair follicule as
evidenced by new selective inhibitors of either type -1 or type -2 human
steroid 5α-reductase
Exp Dermatol, 11, p52-8

HANAKAWA Y, 2002
Expression of desmoglein 1 compensates for genetic loss of desmoglein 3 in
keratinocyte adhesion.
J Invest dermatol., Jul, 119 (1), p27-31

JAHODA C. ve ark., 1992

Changes in fibronectin,laminin and type IV collagen distribution relate to
basement membrane restructuring during the rat vibrissa follicle hair growth
cycle.
J Anat, 181, p 47-60

JONAK C ve ark., 2002

Subcorneal colocalization of the small heat shock protein, HSP27, with
keratins and proteins of the cornified envelope.
Br J Dermatol., Jul, 147 (1), p13-9

KROHN ve ark., 2003

1,25(OH)(2)D(3) and Dihydrotestoste Interact to regulate Proliferation and
Differentiation of Epiphyseal Chondrocytes.
Calcif. Tissue Int. 2003 Jul. 24

MAQUART FX, ve ark., 1999

Régulation de l’activité cellulaire par la matrice extracellulaire : le concept
de Matrikines
Journal de la Société de Biologie, 193, (4), p 423

NUBER UA ve ark., 1996

Patterns of desmocollins synthesis in human epithelia: immunolocalization of
desmocollin 1 and 3 in special epithelia and in cultured cells
Eur J Cell Biol, sep, 71 (1), p1.13

PAUS R., 1999

A comprehensive guide for the recognition and classification of distinct stages
of hair follicle morphogenesis.
The Society for Invest. Dermatol.

PHILPOTT MP, ve ark., 1996

Whole Hair Follicule culture
Dermatologic Clinics, oct, 14 (4), p595-607

VAN NESTE D ve ark., 2000

Finasteride increases anagen hair in men with androgenetic alopecia.
British J of Dermatol., 143, p804-10

PROCAPIL™
 40/41
ROUSSELLE P, 2003
Laminine 5 et réparation de l’épiderme.
COBIP, Séminaire d’enseignement, LYON, 2003

SAWAYA ME ve ark., 2001

Androgen responsive genes as they affect hair growth.
Eur J Dermatol., Aug, 11 (4), p304-8

SHELLEY W.B. ve ark., 1985

Uncombale hair syndrome: observations on response to Biotin and
occurrence in sibbings with ectodermal dysplasia.
J Am Acad Dermatol, 13 (97), p97-102

SUORMALA T ve ark., 2002

Biotin-dependent carboxylase activities in different CNS and skin-derived
cells, and their sentivity to biotin-depletion.
Int J Vitam Nutr Res , 72 (4),p278-86

TAMIOLAKIS D ve ark., 2001

Expression of laminin , type IV collagen and fibronectin molecules is related to
embryonal skin and epidermal appendage morphogenesis.
Clin Exp Obstet Gynecol, 28 (3), p179-82

ZHANG YH ve ark.., 2000

Endothelium – dependent vasorelaxant and antiproliferative effects of
apigenin.
Gen. Phamacol., 35 (6), p341-347

WARREN R ve ark., 1992

Improved method for the isolation and cultivation of human scalp dermal
papilla.
JJ Invest. Dermatol., 98 (5), p 693.

PROCAPIL™
 41/41
EK

Klinik deney için kullanŦlan formülasyonlar

BaƔlangŦĕ materyali INCI adŦ Tedarikçi Plasebo Ürün

% %
$úDPD
Demineralize su Water (Aqua) Yet. 100 Yet. 100
Sitrik asit Citric Acid 0.26 0.26
Sodyum sitrat Sodium Citrate 1.20 1.20
Inkrokuat CTC 30 Cetrimonium Croda 1.00 1.00
Chloride
$úDPD
Etanol Ethanol 8.00 8.00
Parfüm Fragrance Yet. Yet.
Krillet 1 Polysorbate 20 Croda 0.40 0.40
$úDPD
PROCAPIL™ (bkz. Özet) SEDERMA - %3
PROCAPIL™ eksipiyan %3 -

PROCAPIL™
ACTIVE

Sederma SAS
29, rue du Chemin Vert
F-78612 Le Perray en Yvelines
Tel ++ 33 1 34 84 10 10
Faks ++ 33 1 34 84 11 30
sederma@sederma.frwww.seder
ma.fr

Sederma, Inc.
300-A Columbus Circle
Edison, NJ 08837 ABD
Tel ++ (732) 692 1652
Faks ++ (732) 417 0804
sederma-
usa@croda.comwww.croda
usa.com

Sederma GmbH
Herrenpfad-Süd 33
41334 Nettetal Almanya
Tel ++ 49 21 57 817318
Faks ++ 49 21 57 817361
sederma@sederma.dew
ww.sederma.fr

Sederma © 2004-2009

Croda International Plc. üyesidir